CNS drugs
Page 1: CNS Drugs And Behavior
Page 2: Depression
Definition: Clinical depression differs from regular sadness; mood persists and affects daily activities.
Page 3: Symptoms of Depression
Common symptoms include:
Feelings of worthlessness or hopelessness
Changes in weight/appetite
Fatigue/loss of energy
Agitation or irritability
Difficulty concentrating
Thoughts of death or suicide
Contributing factors: loss, stress, hereditary.
Page 4: Theoretical Chemical Basis of Depression
Amine Hypothesis of Mood: Depression may stem from decreased neurotransmitter activity impacting mood.
Neurotransmitter Receptor Hypothesis: Antidepressants alter receptor sensitivity, correlating better with clinical improvement over time.
Page 5: Antidepressants: Clinical Uses
Types: TCAs, MAOIs, SSRIs, SNRIs.
Applications beyond depression: anxiety, OCD, eating disorders, PTSD, and chronic pain management.
Page 6: Clinical Use: Tricyclics
Prototypes: Imipramine, Amitriptyline.
Indications: Endogenous depression and various non-depression uses like bed-wetting, chronic pain.
Not effective on an "as needed" basis.
Page 7: Side Effects and Drug Interactions of TCAs
Notable side effects: anticholinergic effects, sedation, and cardiotoxicity.
Caution with epinephrine in local anesthesia due to potential interactions.
Page 8: Monoamine Oxidase Inhibitors
Examples: Phenelzine, Tranylcypromine - used as third-line drugs.
Risks: "Wine and Cheese Syndrome" due to tyramine.
Severe interactions with meperidine.
Page 9: 2nd Generation or Atypical Antidepressants
Examples: SSRIs (Fluoxetine, Sertraline), SNRIs (Venlafaxine), and others.
Advantages: Fewer side effects; suitable for those who cannot tolerate TCAs or MAOIs.
Page 10: SSRI Adverse Effects
Increased suicide risk in youth, bruxism, sexual dysfunction, and serotonin syndrome.
Page 11: Bupropion (Wellbutrin, Zyban)
Mainly a DA reuptake inhibitor, also used for smoking cessation.
Higher seizure risk; avoid in seizure disorder patients.
Page 12: SNRIs
Examples include Venlafaxine and Duloxetine; used to treat depression and anxiety.
Side effects: nausea and insomnia; interactions similar to TCAs.
Page 13: Efficacy of Placebo vs. Antidepressants
Placebo shows significant improvement in depression, with some studies indicating comparable results to medications.
Page 14: Antidepressant Efficacy on Depression Severity
Efficacy increases with severity; minimal benefits seen in mild/moderate cases.
Page 15: Ketamine for Depression
Promising rapid relief for depression; theorized to regenerate brain cells damaged by stress.
Page 16: Bipolar Disorder Overview
Mood spectrum includes extreme mania and severe depression.
Page 17: Bipolar Disorder: Symptoms
Depressive Symptoms: sadness, irritability, fatigue.
Manic Symptoms: exaggerated optimism, decreased sleep, impulsive behavior.
Page 18: Bipolar Disorder: Course
Onset often in early 20s; episodes can be triggered by stress; varying duration and abrupt endings.
Page 19: Mood Stabilizers in Bipolar Management
Lithium: Risk factors include narrow therapeutic index.
Valproic Acid: First choice for rapid cyclers.
Page 20: Sample Medication Regimens for Bipolar Patients
Different combinations include mood stabilizers, atypicals, and antidepressants.
Page 21: Important Interactions With Antidepressants
Drug interactions can lead to hypertensive crises; serotonin syndrome risks known.
Page 22: Antipsychotic Medications - Overview
Notable categories and applications in psychiatric management.
Page 23: Medical Uses of Antipsychotic Medications
Treat schizophrenia, bipolar disorder, nausea/vomiting, and other conditions.
Page 24: Schizophrenia Overview
Prevalence rates and demographics concerning schizophrenia are discussed.
Page 25: Genetic Risk Factors of Schizophrenia
Increased risk for relatives of affected individuals; environmental stressors also contribute.
Page 26: Symptoms of Schizophrenia
Positive Symptoms: Hallucinations, delusions.
Negative Symptoms: Avolition, flattened affect, social withdrawal.
Page 27: Antipsychotic Pharmacotherapy: Typical Antipsychotics
Examples: Chlorpromazine, Haloperidol - mechanisms discussed.
Page 28: Site of Action of Traditional Antipsychotic Agents
Effects on CNS pathways lead to specific pharmacological effects.
Page 29: Extrapyramidal Movement Disorders (EPS)
Types of EPS and their presentations are described in detail.
Page 30: Activity at Other Receptors
Side effects relating to anticholinergic and antihistaminic actions.
Page 31: Antipsychotic Pharmacotherapy: Atypical Antipsychotics
Examples: Clozapine, Olanzapine - improved tolerability noted.
Page 32: Atypical Antipsychotics Comparison
Comparative efficacy focusing on side effects and potency.
Page 33: Dental Management Issues
Importance of oral hygiene in patients on antipsychotics due to xerostomia and side effects.
Page 34: Additional Dental Considerations
Addresses medication interactions and patient comprehension issues.
Page 35: Recommended Dental Practices
Suggestions for improving dental care compliance among patients.
Page 36: Anxiety Disorders Statistics
Prevalence and treatment rates discussed along with the role of dentists.
Page 37: Anxiety vs. Fear
Definitions and distinctions between emotional states of anxiety and fear.
Page 38: Phobias and Panic Attacks
Types of phobias and symptoms of panic attacks delineated.
Page 39: ANXIOLYTICS
Used in various anxiety disorders; limitations of chronic benzodiazepine use mentioned.
Page 40: Classification of Anxiety Medications
Various drug classifications along with examples.
Page 41: Benzodiazepines
Mechanism and effects, risks of tolerance and dependency emphasized.
Page 42: Adverse Effects of BZDs
Side effects range including sedation, tolerance, and cognitive impairment.
Page 43: Dental Relevance Alert
Important considerations for dental procedures concerning BZDs.
Page 44: Comparison of Benzodiazepines & Buspirone
Differences in mechanism, effects, and safety profile discussed.
Page 45: Anticonvulsants Overview
Context of use and various antecedents of seizures addressed.
Page 46: Introduction to Seizures
Types and nature of epileptic seizures detailed.
Page 47: Generalized Seizures
Discussion on grand mal epilepsy and its characteristics.
Page 48: Absence Seizures
Differences between absence and grand mal seizures highlighted.
Page 49: Status Epilepticus
Definition and immediate management options discussed.
Page 50: Types of Anticonvulsants
Classification of various anticonvulsant medications explained.
Page 51: Sodium Channel Inactivators
Mechanism and notable side effects detailed for Phenytoin and Carbamazepine.
Page 52: Specifics on Sodium Channel Inactivators
Clinical usage and drug interactions highlighted.
Page 53: Type II: GABA Enhancers
Discussion on various GABA facilitation methods.
Page 54: BZDs Mechanism of Action
Mechanism of GABA activity enhancement via BZDs.
Page 55: GABA Enhancers: Barbiturates
Clinical uses, spectrum of activity, and notable side effects.
Page 56: GABA Enhancers: Benzodiazepines
Key considerations in managing seizures with benzodiazepines.
Page 57: Type III: T-calcium Current Blockers
Focus on ethosuximide and its effects.
Page 58: Type IV: Mixed Acting
Mechanisms and alternative uses for lamotrigine, topiramate, and valproic acid.
Page 59: Valproic Acid Considerations
Spectrum of activity, multiple mechanisms, and associated risks.
Page 60: General Dental Concerns
Addresses significant considerations in dental treatment of patients on anticonvulsants.
Page 61: Dental Management of Seizure-Prone Patients
Importance of patient history and emergency preparedness.
Page 62: Anticonvulsants in Peripheral Neuropathies
Use of anticonvulsants for neuropathic pain management.
Page 63: Gabapentin and Pregabalin
Mechanism and use cases including dental considerations.
Page 64: Parkinson's Disease Overview
Symptoms and demographic information detailed.
Page 65: Causes of Parkinson’s Disease
Describes neuronal damage and its implications for movement.
Page 66: Drugs Used to Treat Parkinson’s Disease
Mechanisms of levodopa and the use of carbidopa.
Page 67: Other Parkinson’s Medications
Overview of adjunctive therapies and their effects.
Page 68: Parkinson's Therapy Progression
Treatment strategies detailed from monotherapy to deep brain stimulation.
Page 69: Implications for Dentistry
Highlights dental care considerations for patients with Parkinson's.